$BRAINSTORM CELL THERAPEUTICS(BCLI)$ 10:05 AM EST, 01/08/2015 (MT Newswires) -- BrainStorm Cell Therapeutics       (BCLI) shares were higher nearly 2% in recent trade after saying it       expects to raise about $13 million as holders exercise warrants issued       in June 2014 and said it will issue 1.5 new warrants per warrant       exercised.

      BCLI is trading below the mid-point of the 52-week range between $2.81       and $8.47.

      The developer of adult stem cell technologies for neurodegenerative       diseases said the warrants will be exercised at $5.22 per share, a 4%       premium to the closing price of $5.03 on Wednesday. The new warrants can       be exercised at $6.50 each.

      "We believe the proceeds of this transaction will support our NurOwn       clinical development program in amyotrophic lateral sclerosis and our       plans for expanded development in other indications through 2016," CEO       Tony Fiorino said in a statement.